Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis
- The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's (OTC: RLFTF) for RLF-100 (aviptadil), an inhaled formulation, for sarcoidosis.
- RLF-100 is a synthetic form of vasoactive intestinal peptide.
- Sarcoidosis is a rare disease in which the inflammatory process involves the alveoli (air sacs), small bronchi, and small blood vessels.
- RLF-100 is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.
- Price Action: RLFTF shares closed at $0.24 on Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Penny Stocks Health Care Small Cap FDA General
